292 related articles for article (PubMed ID: 19017999)
1. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury.
Huang Y; Qiao F; Atkinson C; Holers VM; Tomlinson S
J Immunol; 2008 Dec; 181(11):8068-76. PubMed ID: 19017999
[TBL] [Abstract][Full Text] [Related]
2. A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration.
Rohrer B; Long Q; Coughlin B; Wilson RB; Huang Y; Qiao F; Tang PH; Kunchithapautham K; Gilkeson GS; Tomlinson S
Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3056-64. PubMed ID: 19264882
[TBL] [Abstract][Full Text] [Related]
3. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation.
Atkinson C; He S; Morris K; Qiao F; Casey S; Goddard M; Tomlinson S
J Immunol; 2010 Dec; 185(11):7007-13. PubMed ID: 20962256
[TBL] [Abstract][Full Text] [Related]
4. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice.
Sekine H; Kinser TT; Qiao F; Martinez E; Paulling E; Ruiz P; Gilkeson GS; Tomlinson S
Arthritis Rheum; 2011 Apr; 63(4):1076-85. PubMed ID: 21452327
[TBL] [Abstract][Full Text] [Related]
5. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection.
Atkinson C; Song H; Lu B; Qiao F; Burns TA; Holers VM; Tsokos GC; Tomlinson S
J Clin Invest; 2005 Sep; 115(9):2444-53. PubMed ID: 16127466
[TBL] [Abstract][Full Text] [Related]
6. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement.
Alawieh A; Elvington A; Zhu H; Yu J; Kindy MS; Atkinson C; Tomlinson S
J Neuroinflammation; 2015 Dec; 12():247. PubMed ID: 26714866
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Targeted Complement Inhibition in Experimental C3 Glomerulopathy.
Ruseva MM; Peng T; Lasaro MA; Bouchard K; Liu-Chen S; Sun F; Yu ZX; Marozsan A; Wang Y; Pickering MC
J Am Soc Nephrol; 2016 Feb; 27(2):405-16. PubMed ID: 26047789
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.
Banda NK; Levitt B; Glogowska MJ; Thurman JM; Takahashi K; Stahl GL; Tomlinson S; Arend WP; Holers VM
J Immunol; 2009 Nov; 183(9):5928-37. PubMed ID: 19828624
[TBL] [Abstract][Full Text] [Related]
9. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.
Zhu P; Bailey SR; Lei B; Paulos CM; Atkinson C; Tomlinson S
Transplantation; 2017 Apr; 101(4):e75-e85. PubMed ID: 28045880
[TBL] [Abstract][Full Text] [Related]
10. Identifying the Role of Complement in Triggering Neuroinflammation after Traumatic Brain Injury.
Alawieh A; Langley EF; Weber S; Adkins D; Tomlinson S
J Neurosci; 2018 Mar; 38(10):2519-2532. PubMed ID: 29437855
[TBL] [Abstract][Full Text] [Related]
11.
Lei B; Sleiman MM; Cheng Q; Tu Z; Zhu P; Goddard M; Martins PN; Langerude L; Nadig S; Tomlinson S; Atkinson C
Front Immunol; 2021; 12():630581. PubMed ID: 34394069
[TBL] [Abstract][Full Text] [Related]
12. The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models.
Fridkis-Hareli M; Storek M; Or E; Altman R; Katti S; Sun F; Peng T; Hunter J; Johnson K; Wang Y; Lundberg AS; Mehta G; Banda NK; Michael Holers V
Mol Immunol; 2019 Jan; 105():150-164. PubMed ID: 30513451
[TBL] [Abstract][Full Text] [Related]
13. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
14. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.
Rohrer B; Coughlin B; Bandyopadhyay M; Holers VM
J Ocul Pharmacol Ther; 2012 Aug; 28(4):402-9. PubMed ID: 22309197
[TBL] [Abstract][Full Text] [Related]
15. The use of Matrigel combined with encapsulated cell technology to deliver a complement inhibitor in a mouse model of choroidal neovascularization.
Annamalai B; Parsons N; Brandon C; Rohrer B
Mol Vis; 2020; 26():370-377. PubMed ID: 32476817
[TBL] [Abstract][Full Text] [Related]
16. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
17. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice.
He S; Atkinson C; Qiao F; Cianflone K; Chen X; Tomlinson S
J Clin Invest; 2009 Aug; 119(8):2304-16. PubMed ID: 19620784
[TBL] [Abstract][Full Text] [Related]
18. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke.
Elvington A; Atkinson C; Zhu H; Yu J; Takahashi K; Stahl GL; Kindy MS; Tomlinson S
J Immunol; 2012 Nov; 189(9):4640-7. PubMed ID: 23028050
[TBL] [Abstract][Full Text] [Related]
19. A novel complement inhibitor sMAP-FH targeting both the lectin and alternative complement pathways.
Takasumi M; Omori T; Machida T; Ishida Y; Hayashi M; Suzuki T; Homma Y; Endo Y; Takahashi M; Ohira H; Fujita T; Sekine H
FASEB J; 2020 May; 34(5):6598-6612. PubMed ID: 32219899
[TBL] [Abstract][Full Text] [Related]
20. Natural immunoglobulin M-based delivery of a complement alternative pathway inhibitor in mouse models of retinal degeneration.
Annamalai B; Parsons N; Nicholson C; Joseph K; Coughlin B; Yang X; Jones BW; Tomlinson S; Rohrer B
Exp Eye Res; 2021 Jun; 207():108583. PubMed ID: 33878326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
